J Cancer 2018; 9(17):3038-3045. doi:10.7150/jca.26278

Research Paper

The cost of hospital treatment of advanced stage lung cancer patients in a developing South East European country

Jelena Perin1, Bojan Zarić1, Jelica Eremić Đođić2, Zoran Potić1, Marijela Potić1, Vanesa Sekeruš1, Stella Laskou3, Charilaos Koulouris3, Athanasios Katsaounis3, Efstathios Pavlidis3, Stylianos Mantalovas3, Dimitrios Giannakidis3, Nikolaos Michalopoulos3, Aikaterini Amaniti4, Fotis Konstantinou5, Chrysanthi Sardeli6, Yunye Ning7*, Hui Shi7*, Haidong Huang7*, Chong Bai7*, Qiang Li7, Branislav Perin1, Ioannis Passos3, Christoforos Kosmidis3, Isaac Kesisoglou3, Konstantinos Sapalidis3✉

1. Institute for pulmonary diseases of Vojvodina, Faculty of Medicine, University of Novi Sad, Serbia
2. University Educons, Sremska Kamenica, Serbia
3. 3rd Department of Surgery, ''AHEPA'' University Hospital, Aristotle University of Thessaloniki, Medical School, Thessaloniki, Greece
4. Anesthesiology Department, ''AHEPA'' University General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece
5. Thoracic Surgery Department, University General Hospital of Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Greece
6. Department of Pharmacology & Clinical Pharmacology, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece
7. Department of Respiratory & Critical Care Medicine, Changhai Hospital, the Second Military Medical University, Shanghai, 200433, China
* Authors contributed equally to this work.


Assessing the lung cancer treatment costs is necessary in order to estimate the budget impact of new interventions and therapeutic innovations. However, there are few studies regarding the use of resources and costs associated with treatment of lung cancer patients, not only in Serbia, but internationally. The aim of this paper was to assess the hospital costs of diagnosing and treating patients with stage IIIB and IV non-small cell lung cancer. Analysis of costs of care, services, medications and medical supplies, as well as of total hospital costs, was performed. Patients diagnosed with stage IIIB or IV NSCLC in the Institute during the year 2013 were enrolled in the study. A total of 187 patients with stage IIIB or IV NSCLC were analyzed. Total hospital costs were 506.970€, of which nearly two thirds was accounted to costs of services and medications. The mean cost per patient with adenocarcinoma was 3.075€, and for squamous cell lung carcinoma patient 1.943€. Statistically significant difference was shown when comparing mean hospital costs between patients in stage IIIB and stage IV adenocarcinoma, where this cost is higher in patients with stage IIIB. Mean hospital cost per female patient was nearly double as high that of the male patients, although without statistically significant difference. The mean cost for all adenocarcinoma patients was 1.317€, and for only four patients treated with TKI therapy 21.233€. This cost analysis could provide useful information in terms of budget impact of different lung cancer treatments and innovations in Serbia and corresponding developing countries.

Keywords: Lung cancer, Non-small cell lung cancer (NSCLC), EGFR, Health economics, Hospital costs

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
How to cite this article:
Perin J, Zarić B, Đođić JE, Potić Z, Potić M, Sekeruš V, Laskou S, Koulouris C, Katsaounis A, Pavlidis E, Mantalovas S, Giannakidis D, Michalopoulos N, Amaniti A, Konstantinou F, Sardeli C, Ning Y, Shi H, Huang H, Bai C, Li Q, Perin B, Passos I, Kosmidis C, Kesisoglou I, Sapalidis K. The cost of hospital treatment of advanced stage lung cancer patients in a developing South East European country. J Cancer 2018; 9(17):3038-3045. doi:10.7150/jca.26278. Available from http://www.jcancer.org/v09p3038.htm